Found: 72
Select item for more details and to access through your institution.
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
- Published in:
- 2019
- By:
- Publication type:
- journal article
Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 5, p. 1567, doi. 10.1111/dom.15485
- By:
- Publication type:
- Article
Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2402, doi. 10.1111/dom.15092
- By:
- Publication type:
- Article
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 468, doi. 10.1111/dom.14890
- By:
- Publication type:
- Article
All‐cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 1, p. 132, doi. 10.1111/dom.14856
- By:
- Publication type:
- Article
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2071, doi. 10.1111/dom.14805
- By:
- Publication type:
- Article
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1426, doi. 10.1111/dom.14352
- By:
- Publication type:
- Article
Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea).
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 455, doi. 10.1111/dom.14239
- By:
- Publication type:
- Article
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
- Published in:
- European Heart Journal, 2024, v. 45, n. 35, p. 3254, doi. 10.1093/eurheartj/ehae322
- By:
- Publication type:
- Article
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 31, p. 2930, doi. 10.1093/eurheartj/ehad283
- By:
- Publication type:
- Article
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.
- Published in:
- European Heart Journal, 2023, v. 44, n. 24, p. 2170, doi. 10.1093/eurheartj/ehad276
- By:
- Publication type:
- Article
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 1, p. 41, doi. 10.1093/eurheartj/ehac530
- By:
- Publication type:
- Article
Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
- Published in:
- European Heart Journal, 2022, v. 43, n. 42, p. 4469, doi. 10.1093/eurheartj/ehac487
- By:
- Publication type:
- Article
Dapagliflozin for heart failure according to body mass index: the DELIVER trial.
- Published in:
- European Heart Journal, 2022, v. 43, n. 41, p. 4406, doi. 10.1093/eurheartj/ehac481
- By:
- Publication type:
- Article
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
- Published in:
- European Heart Journal, 2021, v. 42, n. 36, p. 3727, doi. 10.1093/eurheartj/ehab560
- By:
- Publication type:
- Article
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
- Published in:
- European Heart Journal, 2020, v. 41, n. 36, p. 3402, doi. 10.1093/eurheartj/ehaa496
- By:
- Publication type:
- Article
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
- Published in:
- European Heart Journal, 2020, v. 41, n. 25, p. 2379, doi. 10.1093/eurheartj/ehaa183
- By:
- Publication type:
- Article
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction: A Post Hoc Analysis of the DAPA-HF Trial.
- Published in:
- Annals of Internal Medicine, 2022, v. 175, n. 6, p. 820, doi. 10.7326/M21-4776
- By:
- Publication type:
- Article
Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 5, p. e2314428, doi. 10.1001/jamanetworkopen.2023.14428
- By:
- Publication type:
- Article
Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 3, p. e234709, doi. 10.1001/jamanetworkopen.2023.4709
- By:
- Publication type:
- Article
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 8, p. 1788, doi. 10.1002/ejhf.3352
- By:
- Publication type:
- Article
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 7, p. 1539, doi. 10.1002/ejhf.3269
- By:
- Publication type:
- Article
Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 7, p. 1524, doi. 10.1002/ejhf.3263
- By:
- Publication type:
- Article
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 963, doi. 10.1002/ejhf.3218
- By:
- Publication type:
- Article
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER.
- Published in:
- European Journal of Heart Failure, 2024, v. 26, n. 4, p. 912, doi. 10.1002/ejhf.3184
- By:
- Publication type:
- Article
Impact of COVID‐19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 12, p. 2177, doi. 10.1002/ejhf.3043
- By:
- Publication type:
- Article
Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 11, p. 2078, doi. 10.1002/ejhf.3000
- By:
- Publication type:
- Article
Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 10, p. 1797, doi. 10.1002/ejhf.2982
- By:
- Publication type:
- Article
Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 10, p. 1831, doi. 10.1002/ejhf.2944
- By:
- Publication type:
- Article
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 9, p. 1663, doi. 10.1002/ejhf.3001
- By:
- Publication type:
- Article
Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 9, p. 1606, doi. 10.1002/ejhf.2962
- By:
- Publication type:
- Article
Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 8, p. 1364, doi. 10.1002/ejhf.2912
- By:
- Publication type:
- Article
Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 7, p. 1170, doi. 10.1002/ejhf.2915
- By:
- Publication type:
- Article
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 7, p. 981, doi. 10.1002/ejhf.2909
- By:
- Publication type:
- Article
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 12, p. 2307, doi. 10.1002/ejhf.2722
- By:
- Publication type:
- Article
Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 10, p. 1856, doi. 10.1002/ejhf.2649
- By:
- Publication type:
- Article
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 6, p. 1066, doi. 10.1002/ejhf.2433
- By:
- Publication type:
- Article
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 3, p. 513, doi. 10.1002/ejhf.2381
- By:
- Publication type:
- Article
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
- Published in:
- European Journal of Heart Failure, 2022, v. 24, n. 1, p. 230, doi. 10.1002/ejhf.2386
- By:
- Publication type:
- Article
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 7, p. 1217, doi. 10.1002/ejhf.2249
- By:
- Publication type:
- Article
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 4, p. 601, doi. 10.1002/ejhf.2124
- By:
- Publication type:
- Article
Effect of dapagliflozin on anaemia in DAPA‐HF.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 4, p. 617, doi. 10.1002/ejhf.2132
- By:
- Publication type:
- Article
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 4, p. 2603, doi. 10.1002/ehf2.13374
- By:
- Publication type:
- Article
Patient characteristics and acute cardiovascular event rates among patients with very high‐risk and non‐very high‐risk atherosclerotic cardiovascular disease.
- Published in:
- Clinical Cardiology, 2021, v. 44, n. 10, p. 1457, doi. 10.1002/clc.23706
- By:
- Publication type:
- Article
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.
- Published in:
- Journal of the American Heart Association, 2024, v. 13, n. 5, p. 1, doi. 10.1161/JAHA.123.032279
- By:
- Publication type:
- Article